Prognostic impact of KRAS mutant type and MET amplification in ...

MET amplification was associated with significantly shorter overall survival. We show for the first time that KRAS mutation and MET ...

Affiliations · PMID: 27014419 · PMCID: PMC4773703 · DOI: 10.18632/genesandcancer.96. Abstract. Receptor tyrosine kinase ( ...

Prognostic impact of KRAS mutant type and MET amplification in ...

Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin.

[PDF] Prognostic impact of KRAS mutant type and MET amplification ...

It is shown for the first time that KRAS mutation and MET amplification are promising predictive markers in metastatic and recurrent GC patients treated ...

(PDF) Prognostic impact of KRAS mutant type and MET amplification ...

Among 144 patients, KRAS mutation was detected in five (3.5%) at codon 12 and one (0.7%) at codon 13. FGFR2, EGFR, HER2, MET and KRAS gene amplification was ...

Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC

KRAS mutations, the most frequent gain-of-function alterations in NSCLC, are currently emerging as potential predictive therapeutic targets.

Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC

KRAS mutations, the most frequent gain-of-function alterations in NSCLC, are currently emerging as potential predictive therapeutic targets.

Incidence and prognostic impact of KRAS and BRAF mutation in ...

On multivariate analysis, KRAS mutation was associated with worse survival (hazard ratio [HR], 1.99; 95% confidence interval [CI], 1.21-3.26), ...

KRAS Mutations as Prognostic and Predictive Markers in Non–Small ...

Nevertheless, the role of KRAS oncogene in non–small-cell lung cancer remains unclear. Recent studies indicated that mutant KRAS could be predictive of lack of ...

The Prognostic Impact of KRAS G12C Mutation in Patients with ...

Median OS for the entire population was 29.4 months (95% CI, 27.9–30.9 months). Compared with patients with wild-type KRAS exon 2, median OS was ...

Prognostic and predictive effect of KRAS gene copy number and ...

It is plausible that gene amplification is acquired in KRAS-dependent tumors to aid in tumor progression. Newnham et al. compared resected and recurrent NSCLC ...

The current understanding on the impact of KRAS on colorectal cancer

A clinical study shows that mutations in KRAS codon 13 is significantly associated with synchronous metastasis and poor prognosis in the CRC patients with lung ...

KRAS mutation is a weak, but valid predictor for poor prognosis and ...

Besides EGFR, KRAS is the most frequently mutated oncogene in NSCLC (15-20%) with most cases affect exon 2 and 3 (G12, G13 and Q61). It seemed ...

KRAS oncogene in non-small cell lung cancer: clinical perspectives ...

In addition to the prognostic impact of the presence of KRAS mutations, concurrent mutations in other genes may have an added prognostic value.

Mutation patterns in a population-based non-small cell lung cancer ...

Here we have evaluated the mutational status of a NSCLC cohort. We could not confirm any survival impact of isolated driver mutations. Instead, ...

Prognostic impact of KRAS mutant type and MET amplification in ...

Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin ...

Tumor microenvironment-adjusted prognostic implications ... - Nature

... type-specific prognostic effect of KRAS mutations ... ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant ...

Clinical characteristic and survival outcomes of patients with ...

Approximatively 25%-30% of non-squamous NSCLC harbor a KRAS mutation (KRASm) in Western countries. These mutations mainly affect codons 12, 13, ...

Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with ...

We evalu- ated the associations among KRAS mutation type, clinical factors, and overall survival in univariate and multivariate analyses. Any significant.

Targeting KRAS Mutant in Non-Small Cell Lung Cancer - Frontiers

As well, KRAS G12C-positive patients present a higher rate of metastasis at diagnosis compared with KRAS wild-type (i.e., 94.4% vs. 88.4%) (32).